Columbia Laboratories, Inc. (Columbia) is engaged in the business of developing, manufacturing and selling pharmaceuticals products that utilize its bioadhesive drug delivery technologies. The Company is focused on the women’s reproductive healthcare market but its product development projects address the women’s healthcare market. Its bioadhesive vaginal gel products provide solutions for infertility, pregnancy support, amenorrhea and other obstetric, gynecologic and medical conditions. The Company’s sales organization in the United States promotes its natural progesterone gel product, CRINONE 8%. It also sells its PROCHIEVE 8% in the United States. CRINONE and PROCHIEVE are two brands of the same product that is approved in the United States for supplementation or replacement of progesterone as part of an assisted reproductive technology (ART) treatment for infertile women with progesterone deficiency and for treatment of secondary amenorrhea.